Comparative outcomes of selective laser trabeculoplasty delivered by optometrists compared with ophthalmologists: a UK-based multicentre observational study.


Journal

BMJ open ophthalmology
ISSN: 2397-3269
Titre abrégé: BMJ Open Ophthalmol
Pays: England
ID NLM: 101714806

Informations de publication

Date de publication:
02 Oct 2024
Historique:
received: 16 07 2024
accepted: 31 08 2024
medline: 3 10 2024
pubmed: 3 10 2024
entrez: 2 10 2024
Statut: epublish

Résumé

Selective laser trabeculoplasty (SLT), a National Institute for Care and Health Excellence recommended first-line treatment for open-angle glaucoma and ocular hypertension, is increasingly delivered by optometrists. This retrospective multicentre observational study evaluates real-world outcomes of SLT comparing optometrist-treated to ophthalmologist-treated eyes. Adults aged ≥40 years receiving first SLT treatment at three UK hospital eye units (Aintree, Manchester, Macclesfield) between 1 August 2018 and 1 August 2021 were analysed using anonymised local audit data. Outcomes included intraocular pressure (IOP), visual acuity (VA), drop burden, complications including post-SLT IOP spikes, and composite treatment failures including repeat laser or glaucoma surgery, evaluated at 6-monthly intervals up to 24 months. Groups were compared with parametric and non-parametric tests, accounting for intereye correlation, and Kaplan-Meier survival analysis using composite treatment failure endpoints was conducted. 207 eyes (131 patients) were analysed, 84 (56 patients) optometrist-treated eyes compared with 123 ophthalmologist-treated eyes (75 patients). No statistically significant differences (p>0.05) were found in change in VA, IOP or glaucoma drops from pre-SLT baseline between optometrist and ophthalmologist-treated eyes, at all time points. More cataracts were detected in optometrist-treated eyes, however, this did not affect differences in VA or cataract surgery frequency. More optometrist-treated eyes underwent glaucoma surgery, however, ophthalmologist-treated eyes had higher drop burden and chance of composite treatment failure up to month 18. Outcomes of SLT treatment by optometrists and ophthalmologists are comparable up to 24 months post-treatment. Ophthalmologist-treated eyes may have had more aggressive eye-drop treatment, preventing the need for surgery.

Sections du résumé

BACKGROUND BACKGROUND
Selective laser trabeculoplasty (SLT), a National Institute for Care and Health Excellence recommended first-line treatment for open-angle glaucoma and ocular hypertension, is increasingly delivered by optometrists. This retrospective multicentre observational study evaluates real-world outcomes of SLT comparing optometrist-treated to ophthalmologist-treated eyes.
METHODS METHODS
Adults aged ≥40 years receiving first SLT treatment at three UK hospital eye units (Aintree, Manchester, Macclesfield) between 1 August 2018 and 1 August 2021 were analysed using anonymised local audit data. Outcomes included intraocular pressure (IOP), visual acuity (VA), drop burden, complications including post-SLT IOP spikes, and composite treatment failures including repeat laser or glaucoma surgery, evaluated at 6-monthly intervals up to 24 months. Groups were compared with parametric and non-parametric tests, accounting for intereye correlation, and Kaplan-Meier survival analysis using composite treatment failure endpoints was conducted.
RESULTS RESULTS
207 eyes (131 patients) were analysed, 84 (56 patients) optometrist-treated eyes compared with 123 ophthalmologist-treated eyes (75 patients). No statistically significant differences (p>0.05) were found in change in VA, IOP or glaucoma drops from pre-SLT baseline between optometrist and ophthalmologist-treated eyes, at all time points. More cataracts were detected in optometrist-treated eyes, however, this did not affect differences in VA or cataract surgery frequency. More optometrist-treated eyes underwent glaucoma surgery, however, ophthalmologist-treated eyes had higher drop burden and chance of composite treatment failure up to month 18.
CONCLUSION CONCLUSIONS
Outcomes of SLT treatment by optometrists and ophthalmologists are comparable up to 24 months post-treatment. Ophthalmologist-treated eyes may have had more aggressive eye-drop treatment, preventing the need for surgery.

Identifiants

pubmed: 39357974
pii: bmjophth-2024-001870
doi: 10.1136/bmjophth-2024-001870
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: RH is an expert witness for the General Optical Council and is a member of the 2022 NICE guideline committee. None of the other authors have competing interests with respect to this study.

Auteurs

Chan Ning Lee (CN)

King's Ophthalmology Research Unit, King's College Hospital, London, UK.
Faculty of Life Sciences and Medicine, King's College London, London, UK.

Alexander Delaney (A)

Department of Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.

Jay A L Richardson (JAL)

Department of Ophthalmology, Manchester Royal Eye Hospital, Manchester, UK.
Manchester Royal Eye Hospital, Manchester Academic Health Sciences Centre, Manchester, UK.

Graham Freeman (G)

Department of Ophthalmology, Macclesfield District General Hospital, Macclesfield, UK.

Patrick J G Gunn (PJG)

Manchester Royal Eye Hospital, Manchester Academic Health Sciences Centre, Manchester, UK.
The University of Manchester Division of Pharmacy and Optometry, Manchester, UK.

Stephen Harthan (S)

Department of Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.

Vincent Dubois (V)

Department of Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.

Kenneth Yau (K)

Department of Ophthalmology, Manchester Royal Eye Hospital, Manchester, UK.

Christopher Hemmerdinger (C)

Department of Ophthalmology, Macclesfield District General Hospital, Macclesfield, UK.

Robert Harper (R)

Manchester Royal Eye Hospital, Manchester Academic Health Sciences Centre, Manchester, UK.
The University of Manchester Division of Pharmacy and Optometry, Manchester, UK.

Neeru A Vallabh (NA)

Department of Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK vallabh@liverpool.ac.uk.
Department of Eye and Vision Sciences, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH